A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : L-AmB / liposomal amphotericin B

[Related PubMed/MEDLINE]
Total Number of Papers: 295
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   L-AmB  (>> Co-occurring Abbreviation)
Long Form:   liposomal amphotericin B
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A case of pediatric visceral leishmaniasis-related hemophagocytic lymphohistiocytosis diagnosed by mNGS. mNGS, VL-HLH
2020 American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate. CL, MA
2020 Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis. MIL, PKDL, qPCR
2020 Case Report: Combination Therapy with Liposomal Amphotericin B, N-Methyl Meglumine Antimoniate, and Pentamidine Isethionate for Disseminated Visceral Leishmaniasis in a Splenectomized Adult Patient. VL
2020 Combination antifungal therapy without craniotomy in an immunocompromised patient with rhino-orbito-cerebral mucormycosis: A case report. ROCM
2020 Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis. CL
2020 High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections. AE, HD-POS
2020 Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropaenia and persistent fever. ivITCZ
2020 Low-dose liposomal amphotericin B for antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell transplantation. IFI
10  2020 Management of cerebral azole-resistant Aspergillus fumigatus infection: A role for intraventricular liposomal-amphotericin B. CNS
11  2020 Minimum concentration of Amphotericin B in serum according to the formulation, dose, and daily or prolonged intermittent therapeutic regimen. HPLC
12  2020 Non-occlusive ST-segment elevated myocardial infarction following the administration of liposomal amphotericin B in the treatment of cryptococcal meningitis. ---
13  2020 Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B. IFI, OPAT, OPAT
14  2020 Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine, oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate. ENT, MCL
15  2020 [Probable rheumatoid meningitis complicated by cryptococcal meningitis: A case report]. CCP, CSF, PSL
16  2019 Antifungal Drugs Influence Neutrophil Effector Functions. AmB, CAS, FLC, IL-8, ISA, MFG, PMN, POS, ROS, VRC
17  2019 Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. ---
18  2019 Comparative study on liposomal amphotericin B and other therapies in the treatment of mucosal leishmaniasis: A 15-year retrospective cohort study. ABLC, AEs, CI, d-AMB, ML, OR
19  2019 Current and emerging medications for the treatment of leishmaniasis. CL, ISC, MCL, VL
20  2019 Design of an Antifungal Surface Embedding Liposomal Amphotericin B Through a Mussel Adhesive-Inspired Coating Strategy. CAUTI, PDA, PDMS
21  2019 Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study. AKI, KDIGO, TAZ/PIPC, VCM
22  2019 Effectiveness of Single-Dose Liposomal Amphotericin B in Visceral Leishmaniasis in Bihar. AE, VL
23  2019 Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis. CIs, IC, OR
24  2019 Efficacy of liposomal amphotericin B and anidulafungin using an antifungal lock technique (ALT) for catheter-related Candida albicans and Candida glabrata infections in an experimental model. ALT, MBEC90
25  2019 Efficacy of T-2307, a novel arylamidine, against ocular complications of disseminated candidiasis in mice. ---
26  2019 In Vitro and In Vivo Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus. ---
27  2019 Invasive Aspergillosis in Pediatric Leukemia Patients: Prevention and Treatment. IA
28  2019 Invasive Fungal Infections While on Voriconazole, Liposomal Amphotericin B, or Micafungin for Antifungal Prophylaxis in Pediatric Stem Cell Transplant Patients. HSCT, IFIs, PAP
29  2019 Invasive mucormycosis in children with cancer: A retrospective study from the Infection Working Group of Italian Pediatric Hematology Oncology Association. AIEOP
30  2019 Liposomal Amphotericin B Fosters the Corticosteroids' Anti-inflammatory Effect on Murine Allergic Bronchopulmonary Aspergillosis Model Airways. ABPM, Af, BALF, DEX, Df, ITCZ
31  2019 Managing invasive aspergillosis in haematological patients in the era of resistance polymerase chain reaction and increasing triazole resistance: A modelling study of different strategies. BAL, IA, PCR
32  2019 Miltefosine Rescue Treatment for Visceral Leishmaniasis Relapse Patient. VL
33  2019 Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. MIC
34  2019 Renal Recovery following Liposomal Amphotericin B-Induced Nephrotoxicity. AKI
35  2019 Rhinoorbital mucormycosis in the immunocompetent: Experience with Isavuconazole. ---
36  2019 Rhodotorula infection in haematological patient: Risk factors and outcome. allo-SCT, CVC
37  2019 Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. CFU, CI, CM, EFA, HIV
38  2019 Treatment for human visceral leishmaniasis: a cost-effectiveness analysis for Brazil. MA
39  2019 Trending serial CSF samples to guide treatment of refractory coccidioidal meningitis with intrathecal liposomal amphotericin. AmB-d, AmBd, CSF, EVD, WBC's
40  2018 A Case of Conjunctival Ulcer and Uveitis Caused by Acrophialophora Sp. in an Immunocompromised Patient: a Case Report and Riterature Review. VRCZ
41  2018 A rare case of visceral leishmaniasis in an immunocompetent traveler returning to the United States from Europe. VL
42  2018 Chemotherapeutics of visceral leishmaniasis: present and future developments. PM, VL
43  2018 Comprehensive drug utilization review in neonates: liposomal amphotericin B. ---
44  2018 Diagnosing Ring-Enhancing Lesions in the Brain of a Patient With AIDS Without Brain Biopsy: A Case of Central Nervous System Histoplasmoma. BM, MRI
45  2018 Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey. IC
46  2018 Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK. IMDs, ISAV, POSA, VORI
47  2018 Efficacy and Safety of Low-Dose Liposomal Amphotericin B in Adult Patients Undergoing Unrelated Cord Blood Transplantation. CBT
48  2018 Efficacy of liposomal amphotericin B against four species of Candida biofilms in an experimental mouse model of intravascular catheter infection. MCFG
49  2018 Epidemiological and clinical features of visceral leishmaniasis in children in Alicante Province, Spain. MA, VL
50  2018 Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis. ABLC, AKI, CF, TEAE
51  2018 Invasive candidiasis and candidemia in pediatric and neonatal patients: A review of current guidelines. D-AmB, IC/C
52  2018 Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B. CL, i.v, PK, qPCR
53  2018 Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis. gDNA, IQR, PKDL, VL
54  2018 Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis. ---
55  2018 Potential Usefulness of Early Potassium Supplementation for Preventing Severe Hypokalemia Induced by Liposomal Amphotericin B in Hematologic Patients: A Retrospective Study. ---
56  2018 Prosthetic Valve Candida spp. Endocarditis: New Insights Into Long-term Prognosis-The ESCAPE Study. aORs, CI
57  2018 Safety and tolerability of intrathecal liposomal amphotericin B (AmBisome) for cryptococcal meningitis: a retrospective study in HIV-infected patients. CM, IQR
58  2018 The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B. eGFR
59  2018 Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis. PM, SSG, VL
60  2017 A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulations. ---
61  2017 A multicenter phase 2 study of empirical low-dose liposomal amphotericin B in patients with refractory febrile neutropenia. IFI
62  2017 An update on the safety and interactions of antifungal drugs in stem cell transplant recipients. HSCT, IFDs
63  2017 Cost-effectiveness of diagnostic-therapeutic strategies for paediatric visceral leishmaniasis in Morocco. BM, RDTs, VL
64  2017 Cutaneous mucormycosis as result of insulin administration in an AML patient: Case report and review of the literature. ---
65  2017 Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial. AE, amphoB, MA, VL
66  2017 Experience with miltefosine for persistent or relapsing visceralleishmaniasis in solid organ transplant recipients: Acase series from Spain. SOT, VL
67  2017 Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. HPLC
68  2017 Hepatotoxicity of Antimycotics Used for Invasive Fungal Infections: In Vitro Results. ANI, CASPO, DILI, FLUCO, VORI
69  2017 In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis. CI, IA, WT
70  2017 Invitro antifungal susceptibilities of Candida species to liposomal amphotericin B, determined using CLSI broth microdilution, and amphotericin B deoxycholate, measured using the Etest. AmB
71  2017 Lack of Efficacy of Liposomal Amphotericin B Against Acute and Chronic Trypanosoma cruzi Infection in Mice. i.v
72  2017 Liposomal amphotericin B (AmBisome) at beginning of its third decade of clinical use. IFD
73  2017 Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea. ---
74  2017 Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis. ---
75  2017 Prognostic factors for death from visceral leishmaniasis in patients treated with liposomal amphotericin B in an endemic state in Brazil. VL
76  2017 Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. ALL, IFD
77  2017 Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies. CI, SHR
78  2017 Saksenaea erythrospora, an emerging mucoralean fungus causing severe necrotizing skin and soft tissue infections - a study from a tertiary care hospital in north India. ITS, LSU, rRNA
79  2017 Short-course Regimens of Liposomal Amphotericin B for the Treatment of Mediterranean Visceral Leishmaniasis in Children: An 11-year Retrospective Study at a Tertiary Care Center. VL
80  2017 Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study. ---
81  2017 [Allergic bronchopulmonary aspergillosis: Evaluation of a maintenance therapy with nebulized Ambisome]. ABPA
82  2017 [Disseminated fusariosis in patients with acute leukemia: a retrospective analysis of three cases]. ALL, EG, MCFG
83  2016 Efficacy of anidulafungin in the treatment of experimental Candida parapsilosis catheter infection using an antifungal-lock technique. ---
84  2016 Invasive fungal infection in neonatal intensive care units: a multicenter survey. IFI, NICUs, SADRs
85  2016 Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children. AUC0-24, HPLC, IFD, PK
86  2016 Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections. BSI, CI, OR
87  2016 Recent developments and future prospects in the treatment of visceral leishmaniasis. VL
88  2016 Safety and efficacy of treatment with liposomal amphotericin B in elderly patients at least 65 years old with hematological diseases. ---
89  2016 Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry. CDC, HD, SD
90  2016 Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin. CST, MIC
91  2016 Visceral leishmaniasis in immunocompromised: diagnostic and therapeutic approach and evaluation of the recently released IDSA guidelines. VL
92  2015 Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life. AML, IPA
93  2015 An update on pharmacotherapy for leishmaniasis. CL, PM, VL
94  2015 Antifungal antibiotics modulate the pro-inflammatory cytokine production and phagocytic activity of human monocytes in an in vitro sepsis model. ANI, ITC, LPS
95  2015 Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients. AFT, c-AmB, DD, IFD
96  2015 Hematological toxicities associated with amphotericin B formulations. ABLC, CI, d-AmB, HIV, OR
97  2015 High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial. AE, CTC, IFI, LT
98  2015 Intravitreal liposomal amphotericin B for treatment of endogenous candida endophthalmitis. ---
99  2015 Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus. ABLC, PD, PK
100  2015 Pharmacokinetic evaluation of liposomal amphotericin B (L-AMB) in patients with invasive fungal infection: Population approach in Japanese pediatrics. AMPH-B, CL, PK, Vc